11th IAS Conference on HIV Science

IAS 2021 – the 11th IAS Conference on HIV Science – is the world’s most influential conference on HIV Science and will be held virtually on 18-21 July 2021.

The biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. IAS 2021 will include a “local partner hub” to convene locally based experts in the original host city of Berlin, in accordance with local health advice and regulations.

The HIV/AIDS Clinical Trials Networks will present research in oral sessions and e-poster formats.

Oral Presentations

Session times are listed in Central European Summer Time (CEST).

Date/TimeProtocolTitlePresenter
July 20, 12:00 - 12:50 CESTMTN-034High adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in AfricaGonasagrie Nair
July 21, 12:00 - 12:50 CESTHPTN 083-02Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGWChristina Psaros
On-DemandHPTN 084Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEPMia Moore
On-DemandMTN-003HPV increases HIV Risk in African Women: Advancing the argument or HPV immunizationGui Liu

E-Posters

All e-Posters are available on-demand.

ProtocolTitlePresenter
HPTN 061Comparisons of associations between incarceration and sexual risk behavior and STI/HIV among Black sexual minority men in Six U.S. cities (HPTN 061)Jonathan Feelemyer
HPTN 068Partnership dynamics and dual method use among adolescent girls and young women in South Africa: a longitudinal analysis of HIV Prevention Trials Network 068 dataNivedita L. Bhushan
HPTN 082Trust in the PrEP provider is associated with accurate self-reported PrEP adherence among adolescent girls and young women in sub-Saharan AfricaGeetha Beauchamp
HPTN 084Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084Sinead Delany-Moretiwe
HVTN 704 / HPTN 085HIV-1 Env markers of prevention efficacy in HVTN 704/HPTN 085, the Antibody-Mediated Prevention (AMP) trial of broadly neutralizing antibody (bnAb) VRC01 in the Americas and Europe: genotypic sieve analysisCraig Magaret
IMPAACT 2019Pharmacokinetics and Safety of Dispersible and Immediate Release FDC Abacavir/ Dolutegravir/ Lamivudine in Children with HIV Weighing ≥14 kg: Preliminary Results from IMPAACT 2019Kristina Brooks
IMPAACT PROMISE 1077BF Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in HIV-1-Infected Postpartum Women in Promoting Maternal and Infant Survival Everywhere (PROMISE): Randomized, Open Label Trial in Sub-Saharan Africa and IndiaNeetal Nevrekar
IMPAACT P1078Prevalence of Depression among Postpartum Women on Isoniazid-Preventive Therapy and Efavirenz-based Treatment for HIV—An Exploratory Objective of the IMPAACT P1078 Randomized TrialKristin Baltrusaitis
MTN-020Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention Among Women Who Exchange SexErica Browne
MTN-042Prioritizing the evaluation of HIV prevention interventions in pregnancy: Interim results from a randomized, open-label safety trial of dapivirine vaginal ring and oral tenofovir disoproxil fumarate/emtricitabine use in late pregnancyKatie Bunge
MTN-045Making the case for joint decision-making: the influence of partner preferences on future dual prevention product useMiriam Hartmann
MTN-045Couples' preferences for a dual-purpose product to prevent both HIV and pregnancy: results of a discrete choice experiment (DCE) in Uganda and ZimbabweAlexandra Minnis